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Abstract
Background/Aim. Critically ill patients are at very high
risk of developing severe infections in intensive care units
(ICUs). Procalcitonin (PCT) levels are eleveted in the circu-
lation in patients with bacterial sepsis and PCT might be
useful in guiding antibiotic treatment. The aim of this study
was to estimate factors influencing patients survival and
treatment cost in ICU with special emphasis on the impact
of PCT serum levels use in guiding antimicrobial therapy.
Methods. The study was conducted from August 2010 to
May 2012 in the Intensive Therapy Unit, Clinic of Anesthe-
siology and Intensive Therapy, Military Medical Academy
(MMA), Belgrade, Serbia. All adult critically ill patients with
sepsis and/or trauma admitted in the ICU were included in
the study. This study included only the cost of antimicrobial
therapy in the ICU and the cost for PCT analysis. We used
prices valid in the MMA for the year 2012. PCT in serum
was measured by homogeneous immunoassay on a Brahms
Kryptor analyzer. Results. A total of 102 patients were en-
rolled. The mean patients age was 55 ± 19 years and 61.8%
of patients were male. The mean length of stay (LOS) in the
ICU was 12 ± 21 days. There was a statistically significant
difference (p < 0.001) between the sepsis and trauma group
regarding outcome (higher mortality rate was in the sepsis
group, particularly in the patients with peritonitis who were
mostly women). The patients younger than 70 years had
better chance of survival. LOS, the use of carbapenems and
PCT-measurement influenced the cost of therapy in the
ICU. Conclusions. The obtained results show that age, the
diagnosis and gender were the main predictors of survival of
critically ill patients in the ICU. The cost of ICU stay was
dependent on LOS, use of carbapenems and PCT-
measurement although the influence of these three factors
on the outcome in the patients did not reach a statistical
significance.
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Apstrakt
Uvod/Cilj. Kritiÿno oboleli pacijenti imaju veliki rizik od
razvoja teških infekcija u jedinicama intenzivne terapije
(JIT). Nivo prokalcitonina (PCT) u cirkulaciji je povišen
kod bolesnika sa bakterijskom sepsom, tako da PCT može
biti koristan u praýenju antibiotske terapije. Cilj ove studije
bio je da se ustanove faktori koji utiÿu na ishod i troškove
leÿenja u JIT u našoj ustanovi sa posebnim naglaskom na
uticaj korišýenja serumskog nivoa PCT u voĀenju antimi-
krobne terapije. Metode. Studija je sprovedena od avgusta
2010. godine do maja 2012. godine u Jedinici intenzivne
terapije Klinike za anesteziologiju i intenzivnu terapiju
Vojnomedicinske akademije (VMA) u Beogradu, Srbija.
Svi kritiÿno oboleli sa sepsom i/ili traumom koji su prim-
ljeni u JIT bili su ukljuÿeni u studiju. Studijom su obuhva-
ýeni samo troškovi antimikrobne terapije u JIT i troškovi
PCT analize. Koristili smo cenovnik VMA za 2012. godi-
nu. PCT u serumu je meren tehnikom homogenog imuno-
eseja na Brams Kriptor analizatoru. Rezultati. Studijom
su bila obuhvaýena 102 bolesnika. Proseÿna starost boles-
nika iznosila je 55 ± 19 godina, a 61,8% bolesnika bili su
muškarci. Proseÿna dužina boravka u JIT (lenght of stay –
LOS) iznosila je 12 ± 21 dana. Postojala je statistiÿki zna-
ÿajna razlika (p < 0.001) izmeĀu ishoda leÿenja u grupi sa
sepsom u odnosu na grupu sa traumom. Bolesnici mlaĀi
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od 70 godina imali su bolju šansu da prežive. Dužina bo-
ravka, upotreba karbapenema i merenje PCT uticali su na
cenu terapije u JIT. Zakljuÿak. Dobijeni rezultati poka-
zuju da su godine života, dijagnoza i pol bili glavni predi-
ktori preživljavanja kritiÿno obolelih u JIT. Cena terapije
zavisila je od dužine boravka u JIT, upotrebe karbapenema
i merenja PCT, ali uticaj ovih faktora na ishod leÿenja nije
dostigao statistiÿku znaÿajnost.
Kljuÿne reÿi:
kritiÿna stanja; sepsa; antibiotici; cene i analize cena;
biološki pokazatelji.
Introduction
Severe infections with multiresistant bacteria represent
a medical challenge and a financial burden for hospitals. Se-
psis is a frequent cause of intensive care unit (ICU) admissi-
on and may also develop in patients admitted to the ICU for
other reasons. Critically ill patients are at very high risk of
developing severe nosocomial infections with the incidence
rate about 5–10-fold higher than in general medical
wards 1, 2. The recent Sepsis Occurence in Acutelly Ill Pati-
ents (SOAP) Study across Europe reported that more than
35% of ICU patients had sepsis at some point during the ICU
stay, with the mortality rate of 27%. In the USA,
approximately 750,000 cases occur each year, at least
250,000 of which are fatal. Septic patients are generally hos-
pitalized for extended periods, sometimes 2–3 weeks 3–6.
The pathophysiology of sepsis is complex and comprises
diffuse endothelial and epithelial injury, increased capillary
permeability, impaired hemodynamics, microvascular throm-
bosis, tissue ischemia, apoptosis and multiorgan failure 7–9.
Critically ill patients with sepsis are commonly treated
with antimicrobials. Selecting the appropriate initial antimic-
robial is most important, since the inappropriate choice may
be responsible for therapeutic failure and higher mortality
rate in ICU 2. The use of inappropriate initial antibiotics may
occur in 34.3% of cases involving nosocomial-acquired bac-
teremia. The risk of death increased from 30–60% in ICU
bacteremia and 70–100% in gram-negative shock when the
initial antimicrobial therapy was inappropriate 7.
The choice of initial empirical anti-infective therapy sho-
uld be broad enough to cover any likely patogens and guided
by local prevalence of microorganisms. Appropriate intrave-
nous antibiotics (e.g. carbapenems, fluoroquinolones) should
be initiated as rapidly as possible, preferably within the first
hour of establishing diagnosis of sepsis 7, 10, 11. The most com-
mon pathogens that cause sepsis in hospitalized patients are
gram-positive bacteria, followed by gram-negative and mixed
bacterial microorganisms. Once blood culture profile results
become available, de-escalation to the most appropriate single-
agent therapy should be performed as soon as possible. This
practice reduces the prevalence of antimicrobial resistance or
the risk of antibiotic related diarrhea from Clostridium diffici-
le, as well as pharmaceutical expenditure 10, 11. However, con-
ventional microbiology cultures, despite their specificity and
accuracy, are time consuming, and a negative result in many
cases of bacterial sepsis (50% or more) does not exclude an in-
fective etiology 10, 12, 13. Procalcitonin (PCT), a prohormone of
calcitonin, was shown to be a marker of sepsis. Its levels are
elevated in the circulation in patients with bacterial sepsis, due
to the failure of suitable proteolysis. PCT has a longer half-life
of 24 to 30 hours in circulation, in contrast to other markers
of sepsis such as tumor necrosis factor (TNF) or interleukin
(IL)-6 2, 14–16. The use of PCT is useful in guiding antibiotic
treatment, but with some limitations. The results derived
from a multicentre randomised controlled trial PRORATA,
show that despite lower antibiotic exposure in the PCT group
compared to the control group, there was no difference
between emerging multidrug-resistant bacteria 17. The results
from a study conducted across Denmark, with 1,200 critically
ill patients, show that PCT-guided antimicrobial strategy does
not improve a 28-day survival. The authors observed deleteri-
ous effects on organ function and length of stay (LOS) in the
ICU in the PCT-guided group 15. Another limitiation for the
use of PCT is associated with the cost of analysis.
Pharmacoeconomics is a scientific discipline that evalua-
tes pharmaceutical interventions, taking into account both the
cost and the value of health benefits. When performing phar-
macoeconomic evaluations of ICU expenditure, it is customary
to consider only the direct price of medication. The single most
important factor determining the magnitude of cost is the LOS
in the ICU, which is influenced by the high mortality in severe
sepsis and septic shock patients and the high incidence of noso-
comial infections in critically ill patients 18, 19.
The aim of this study was to provide data about the cost
and outcome of critically ill patients admitted to our ICU.
We analyzed factors that influence survival of critically ill
patients and the cost of treatment in the ICU. Moreover, the
impact of PCT measurement on the patient survival and cost
of treatment was analysed. Our data are derived from real-
life clinical population of critically ill patients in the ICU.
Methods
The observational study was conducted from August
2010 to May 2012 in the Intensive Therapy Unit of the Clinic
of Anesthesiology and Intensive Therapy of the Military Me-
dical Academy (MMA), tertiary university hospital in Belgra-
de, Serbia. All adult critically ill patients with sepsis and/or
trauma admitted to the ICU were included in the study.
The study was approved by the Ethic Committee in the
MMA and performed in accordance with the Declaration of
Helsinki. Sepsis, severe sepsis and septic shock were diagno-
sed according to the criteria proposed by the American Col-
lege on International Sepsis Definition Conference 20. Com-
plete medical data for all patients were recorded until their
discharge or death.
This study included only the cost of antibacterial
therapy in the ICU. We analyzed cost-related expenditures
such as a total drug cost and the cost for PCT analysis. Costs
related to equipment usage, estates (e.g. cost related to infra-
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structure, electricity, etc) and non-clinical support services,
as well as indirect cost (productivity loses), were not inclu-
ded. The enrolled patients were assessed during ICU stay.
After completion of data collection, all costs were priced.
We used prices valid in the MMA for the year 2012. All the
costs are presented in RSD (Serbian currency). As we col-
lected data from 2010, we adjusted all values using a 10%
average inflation rate to 2012 values, according to Serbian
indexes for that period. In order to compare our data with ot-
hers, we presented costs in euro (€), as well. The exchange
rate of 1€ was considered as 115 dinars for the year 2012.
PCT in serum was measured by homogeneous immuno-
assay (sandwich principle) using time resolved amplified
cryptate emission (TRACE) technology on Brahms Kryptor
analyzer.
The results are expressed as mean ± standard deviation
(SD) for variables that exhibit normal distribution. All costs
are reported as median, with the interquartile range (IQR)
and 95% confidence interval (CI) 21. Statistical analyses were
conducted using PASW 18.0 (SPSS Inc., Chicago, IL, USA).
Binary logistic regression was used to determine the predic-
tors of survival and linear regression was used to determine
the predictors of treatment cost. The results were presented
with odds-ratio (OR) or p-value. Both models were obtained
using a stepwise approach, variables were excluded at the
selection threshold of 0.1. A probability value of < 0.05 was
considered to be statistically significant.
Results
A total of 102 patients were enrolled. The mean patients
age was 55 ± 19 years and 61.8% of patients were male. The
reasons for ICU admissions were severe trauma, severe tra-
uma and secondary sepsis, severe sepsis due to peritonitis,
pancreatitis and other causes. The mean length of ICU stay
was 12 ± 21 days (Table 1).
Regression analysis revealed that gender, the diagnosis
and age influenced the survival of critically ill patients with
sepsis. There was a difference between males and females
regarding the diagnosis. In the sepsis group (regardless of
underlying cause) there were 49 (58.3%) males vs 35
(41.7%) females, whereas in the trauma group (with or
without secondary sepsis) males strongly dominated with 14
(77.8%) vs 4 (22.2%) of females. In the sepsis group with pe-
ritonitis females were dominant. Regression analysis showed
that gender influenced the outcome. The mortality rate in
males was 42.9% and they had better chances to survive (OR
= 2.13). Consequently, there was a statistically significant
difference (p < 0.001) between the sepsis and the trauma
group regarding the outcome; in the trauma group the
mortality rate was 17.6% while in the sepsis due to peritoni-
tis, for example, the mortality rate raised to 48%. The out-
come, among other parameters, was related to age of the stu-
died population. In survivors, the mean age was lower (44 ±
16 years), compared to non-survivors (66 ± 15 years) (p <
0.001). The younger patients (< 70 years) had better chance
of survival (Figure 1).
Survived
Lethal
Age (years)
Fig. 1 – Correlation of age and outcome of survivors and
non-survivors.
Table 1
Demographic and clinical characteristics of critically ill patients
Characteristics Value
Total number of patients (n) 102
Age (years), mean ± SD (range) 55 ± 19  (18 - 87)
Sex, n (%)
  male 63 (61.8)
  female 39 (38.2)
SAPS II score, mean ± SD 56.82 ± 9.83
APACHE II score, mean ± SD 21.87 ± 4.21
SOFA score, mean ± SD 7.56 ± 2.30
Length of ICU stay in days, mean ± SD (range) 12 ± 21 (2–169)
Severe trauma (ISS 28.73 ± 9.40), n (%) 18 (17.6)
Severe trauma and secondary sepsis, n (%) 17 (16.7)
Severe sepsis due to peritonitis, n (%) 49 (48)
Pancreatitis, n (%) 13 (12.7)
Other causes, n (%) 5 (4.9)
Blood cultures, n (%)
  gram-positive 16 (15.7)
  gram-negative 4 (3.9)
  mixed 47 (46.1)
  fungi 1 (1)
  sterile 34 (33.3)
Mortality, n (%) 51 (50)
APACHE II – Acute and Physiology and Chronic Health Evaluation II; SAPS – Simplified Acute Physiology Score II;
SOFA – Sequential Organ Failure Assessment; ICU – Intensive Care Unit; ISS – Injury Severity Score.
Volumen 71, Broj 12 VOJNOSANITETSKI PREGLED Strana 1105
Periý A, et al. Vojnosanit Pregl 2014; 71(12): 1102–1108.
Examining costs and the outcome in 102 patients in the
ICU, irrespective of the underlying cause of admission, we
found that the median cost per patient was higher in 51 non-
survivors compared to 51 survivors (€ 488 vs € 358,
respectively), but regression analysis showed that survival
did not influence ICU cost significantly. In contrast, LOS,
the use of carbapenems and PCT-measurement influenced
the cost of therapy in the ICU (Figures 2–4 and Table 2).
Antibiotics were administered to all patients during ICU
stay. Monotherapy was administered to 32 (31.4%) patients.
Our analysis showed that the most prescribed antibiotics
were carbapenems (58.8%). In the carbapenem group, 56.9%
of patients survived. In non-carbapenem group, 43.1% of
patients survived. Although there was an obvious trend of in-
creased survival in the carbapenem group, it did not reach a
statistical significance. On the other hand, the use of carba-
penems (meropenem or imipenem) significantly increased
the cost of ICU therapy (p < 0.001).
The majority of patients had combined antimicrobial
therapy (68.6%). The combination of antibiotics depen-
ded on clinical and microbiological data, and antimicro-
bial therapy was introduced and managed by the infecti-
ous disease (ID) specialists. Those ID specialists were
consultants from the Clinic for Infectious and Tropical
Diseases of the MMA, and not attending physicians from
the ICU. Our study showed that several combinations of
antibiotics were used in the studied period. Some of them
included carbapenems and vancomycin or carbapenems
and aminoglycosides (gentamycin or amikacin). The ot-
her usual combination was cephalosporins with
vancomycin.
PCT measurement was introduced on the proposal of
ID specialists, in order to control the length of antimicrobi-
al therapy, bacterial resistance, and to reduce the use of an-
timicrobials as well as the cost of antimicrobial therapy.
During the follow-up period, the observed patients were di-
vided into two groups: the PCT-guided group of 56
(54.9%) patients and the non-PCT-guided group of 46
(45.1%) patients. Our results show that in the PCT-guided
group the cost of antimicrobial therapy in the ICU was
significantly higher than in the non-PCT-guided group
(761.56 € vs 329.98 €, respectively; p < 0.001). The diffe-
rences between the cost and the outcome are shown in Ta-
ble 2. There was no significant difference between the out-
come and the length of use of antibiotics in the two groups.
Our results show that 75% of the patients in the PCT-
Fig. 2 – Length of stay in Intensive Care
Unit.
Fig. 3 – Cost of treatment with
meropenem.
Fig. 4 – Cost of treatment with
imipenem/cilastatin.
Table 2
Comparison of cost and outcome in critically ill patients with and with no procalcitonin (PCT)
guided antibiotic therapy
Parameter Survivors(median; IQR; 95% CI)
Non-survivors
(median; IQR; 95% CI)
PCT-guided therapy
- in RSD 75,729.15; 33,984.60-107,941.06;
59,385.51-98,001.47
91,278.23; 56,797.17-125,294.68;
71,138.43-126,056.18
- in € 658.51; 343.97-888.09;
516.40-852.19
793.72; 493.89-1,089.52;
618.60-1,096.14
Non PCT-guided
therapy
- in RSD 71,729.15; 29,984.60-103,941.06;
55,385.51-94,001.47
87,278.23; 52,797.17-121,294.68;
 67,138.43-122,056.18
- in € 623.73; 322.78-800.03;
510.20-893.87
758.94; 405.46-989.79;
598.98-1,001.12
LOS in the PCT
group (days)
34; 19-57; 28.01-58.57 26; 11-57; 22.29-94.11
LOS in non-PCT
group (days)
22; 14-39.50; 18.57-42.67 15; 12-31.5; 13.48-41.16
LOS – lenght of stay in Intensive Care Unit; IQR – interquartile range; CI – 95% confidence interval.
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guided group had combined antibiotic therapy, and 40.5%
of them died. In the PCT-guided group, carbapenems were
administered in 69.6% of the patients and 56.4% of them
survived. The most prescribed was meropenem. In the
PCT-guided group, 41.1% of the patients had mixed bacte-
ria in blood culture and 23.2% of them died. Sterile blood
cultures were found in 33.9% of the patients and 10.7% of
them died.
In the non-PCT guided group, 60.9% of the patients had
combined antibiotic therapy and 50% of them died. Carba-
penems were administered in 45.7% of the patients in the
non-PCT guided group and 33.3% of them survived. In this
group, 52.2% of the patients had mixed bacteria in blood
cultures, out of whom 45.6% died. The differences between
PCT-guided group and non-PCT guided group did not reach
a statistical significance.
Discussion
In the present observational study, three factors were
identified as the major cost drivers: duration of ICU-LOS;
cost of antimicrobial therapy; PCT-measurement.
In our population of critically ill patients, the mortality
rate was 50%. This outcome is comparable with that found
previously in larger studies, where high mortality rates,
between 40% and 70%, were common in ICU if septic shock
developed 6, 18, 22, 23. Moreover, ICU patients had a
significantly increased mortality risk and a decrement in the
quality of life and continued to die in the months and years
after hospital discharge 20, 24, 25.
Patients who stay longer in the ICU are at increased
risk of infection and probably would have higher cost since
LOS is a major determinant of cost. A prolonged ICU stay
consumes a large part of ICU resources. According to the
literature, predominantly because of the long ICU-LOS, the
cost of treatment for patients with sepsis is considerably
higher than treatment for other ICU patients. The ICU di-
rect costs per day are generally three to seven times higher
than for non-ICU care 26, 27. A multicenter, prospective
pharmacoeconomic study of septic patients, showed that
the cost of non-survivors increased day by day, while the
cost of survivors decreased after the first few days. These
findings suggest that patients who developed less organ
dysfunction would have consequent reduced cost 17, 18, 27. In
the United States, the mean hospital cost per patient was
estimated at $ 22,100 with higher cost in infants, patients
who died, ICU patients, surgical patients and patients with
multiple organ dysfunction 5. In three ICUs in Germany
similar results were found and again, total direct hospital
costs were higher in non-survivors, surgical patients and
patients requiring emergency procedures  26. Our results al-
so show the tendency of increased ICU cost in non-
survivors. The lack of statistical significance may be attri-
buted to the relatively small number of patients and great
variability of cost.
Our costs were determined according to the pricing of
drugs used during ICU-LOS in the hospital and those values
are smaller than mentioned in other studies. This may be
explained by the difference in pricing of drugs as well as the
difference of the type of costs which were considered in
comparing studies and included cost of diagnostic methods,
surgical procedures, laboratories tests, microbiological tests,
hospital fee, salaries and workload in ICU.
The most frequently used antibiotics in our study were
carbapenems, which is in accordance with guidelines for an-
tibotic treatment of sepsis 10, 12. Carbapenems, especially me-
ropenem, are antibiotics typically used in ICUs worldwide.
The results of different studies show that meropenem is a
cost-effective alternative to imipenem/cilastatin or piperacil-
lin/tazobactam – the preferred carbapenem unless other fac-
tors affect this decision (such as local pathogen resistan-
ce) 18, 19, 28–30. However, in our study carbapenems increased
the cost of therapy in the ICU. As mentioned before, our po-
pulation of patients was not analyzed in controlled environ-
ment, so our results were observational and from a follow-up
period and may vary from the results derived from predefi-
ned study and the control groups. This might be one of the
possible explanations of the fact that although there was the
obvious trend of increased survival in the carbapenem group,
it did not reach a statistical significance. Further controlled
studies should be conducted in order to get additional data
about clinical and economic benefits of the use of carbape-
nems in our ICU.
PCT measurement is also important in guiding durati-
on of antibiotic therapy in ICU patients and in differentia-
ting infective and non-infective inflammatory conditi-
ons 12, 14, 15, 31. Since the levels of PCT rise in response to
infection, its utility for the diagnosis of infection has been
extensively investigated with conflicting results depending
on the setting and population studied 17, 32. The existing lite-
rature supports the position that PCT-guided therapy is as-
sociated with the average of 2 days of reduction in antibio-
tic use 33. We did not have a reduction in antibiotic use in
PCT-guided group, despite the fact that the ID specialist
was in charge of antibiotic treatment. We are currently mis-
sing tools to facilitate the discontinuation of antibiotics in
the ICU. In standard practice, duration of antibiotic courses
in ICU vary greatly. In critically ill patients on prolonged
therapy with broad-spectrum antibiotics, superinfections
may occur and should be carefully monitored as possible
infectious complications. The duration of antimicrobial
therapy should be limited to 7 to 10 days. According to the
literature, combination therapy should be used in Pseudo-
monas infections and should be discontinued in 3 to 5
days 7. The severity of presenting symptoms correlate with
the mortality in ICU patients and is used to justify more
prolonged therapy. In one recent survey, critical care and
infectious disease specialists were not even completely
swayed by the evidence that limiting antibiotics attenuates
the emergence of resistant Gram-negatives in ICU 5, 34–36. A
small number of antibiotic-free days (e.g. 3 days in a
PRORATA trial) might not be sufficient to record a decrea-
sed resistance-emergence rate, especially for some ICUs
with high cross-transmission rates 17. Our results show that
PCT did not affect the LOS in ICU and that LOS depended
on diverse clinical characteristics and reasons for admissi-
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ons to ICU. In our population of patients, antibiotic treat-
ment was independent on PCT use and the mean duration
was 7 days. These findings are similar to others 35,36.
The price of PCT analysis is about € 35 in our laboratory
which is higher than in France, where PCT analysis costs €
10–15, and is comparable to the expenditure of unnecessary
antibiotics. Nevertheless, Vandjick et al. 37 reported that the
acquisition cost of antibiotics used to treat nosocomial bloods-
tream infections in ICU in adults was € 114 daily. Clearly, we
need more data to confirm the value of PCT as a diagnostic
parameter to guide antibiotic therapy.
The main limitation of our study lies in the number of
patients and the use of direct medication pricing cost only.
Despite this limitation, our results are the real-life results,
obtained in population of critically ill patients and those re-
sults represent valuable data about clinical and economic as-
pects of antibiotic usage.
Conclusion
The obtained results show that age, the diagnosis and
gender were the main predictors of survival of critically ill
patients in the Intensive Care Unit. However, the cost of In-
tensive Care Unit treatment was not significantly influenced
by the survival of patients possibly due to a relatively small
number and large variability of treatment cost. In contrast,
cost of Intensive Care Unit stay was determined by the
lenght of stay, use of carbapenems and procalcitonin-
measurement, although the influence of these three factors
on the outcome in patients did not reach statistical signifi-
cance. To our knowledge, this type of cost analysis is rarely,
if ever, performed routinely. With direct connecting econo-
mic analysis to routine data collections, as we did in our real-
life study, the results would be better and more applicable in
everyday practice.
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